CM
XERS icon

Castleark Management’s Xeris Biopharma Holdings XERS Stock Holding History

Castleark Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-445,950
Closed -$3.5M – 345
2025
Q4 		$3.5M Buy
+445,950
New +$3.51M 0.1% 173

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Castleark Management's XERS Position: Q1 2026 in Review

Castleark Management sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 445,950 shares — an estimated $3.5M sold.

Castleark Management first reported a position in XERS in Q4 2025 and held it in 1 quarter. The position peaked at $3.5M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Castleark Management reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
  • Castleark Management sold 445,950 Xeris Biopharma Holdings shares in Q1 2026, an estimated $3.5M.
  • Castleark Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 1 quarter.
  • Castleark Management's Xeris Biopharma Holdings position peaked at $3.5M in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.